// App-Quantinova.ai

: Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial

Researchers

Presenter

  • Robyn Kendall

Principal Investigators

  • Soham Shukla

  • Alan Martin

  • Dhvani Shah

  • Dawn Midwinter

  • Isabelle Boucot

  • Nancy A. Risebrough

  • Paul Jones

  • Chris Compton

  • Afisi Ismaila

Medical Centers

  • GlaxoSmithKline plc, Collegeville, United States of America

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • ICON Health Economics, ICON plc, Vancouver, Canada

  • ICON Health Economics, ICON plc, Toronto, United States of America

  • GlaxoSmithKline Plc, Brentford, United Kingdom

  • ICON Health Economics, New York, United States of America

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

Drug/Treatment

  • fluticasone furoate/umeclidinium/vilanterol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT03467425

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved